Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma
Abstract Objective TQB3602 is a novel orally bioavailable proteasome inhibitor. This study is the first‐in‐human phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of TQB3602 in relapsed/refractory multiple myeloma (RRMM). Methods This is a multic...
保存先:
| 主要な著者: | , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wiley
2024-07-01
|
| シリーズ: | Cancer Medicine |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1002/cam4.7435 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|